Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.24.1.1.u2
Consolidated Statements of Operations - USD ($)
shares in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Collaboration revenue $ 0 $ 68,000,000 $ 82,000,000
Operating expenses:      
Research and development 716,000,000 677,000,000 697,000,000
Selling, general and administrative 119,000,000 129,000,000 116,000,000
Goodwill impairment 0 1,114,000,000 0
Total operating expenses 835,000,000 1,920,000,000 813,000,000
Loss from operations (835,000,000) (1,852,000,000) (731,000,000)
Other income (expense):      
Change in fair value of derivative liabilities (20,000,000) 114,000,000 (20,000,000)
Other income (expense), net 59,000,000 15,000,000 (9,000,000)
Loss before income taxes (796,000,000) (1,723,000,000) (760,000,000)
Income tax benefit 0 0 (5,000,000)
Net loss $ (796,000,000) $ (1,723,000,000) $ (755,000,000)
Basic net loss per share (in usd per share) $ (0.60) $ (1.51) $ (1.22)
Diluted net loss per share (in usd per share) $ (0.60) $ (1.51) $ (1.22)
Basic weighted-average shares outstanding (in shares) 1,327 1,143 621
Diluted weighted-average shares outstanding (in shares) 1,327 1,143 621